REG - Genedrive PLC - Publication of Circular and Notice of GM

GenedriveAnnouncement

24/04/2023 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230424:nRSX2438Xa&default-theme=true

RNS Number : 2438X  Genedrive PLC  24 April 2023

genedrive plc

 

("genedrive", the "Group" or the "Company")

 

Publication of Circular and Notice of General Meeting

 

London, UK - 24 April 2023: genedrive plc (LSE: GDR), the point of care
molecular diagnostics company, announces that further to the announcement on
31 March 2023 confirming that it had agreed terms on an Equity Prepayment
Facility for up to £5 million, a Circular will shortly be published on the
Company's website, www.genedriveplc.com, and will be posted to Shareholders
later today.

 

The Circular contains the notice convening the General Meeting to be held at
11.00 a.m. on 11 May 2023 at which resolutions will be proposed to authorise
the allotment of new ordinary shares and the disapplication of pre-emption
rights.

 

For further information, please contact:

 

 genedrive plc                         +44 (0) 161 989 0245
 David Budd (Chief Executive Officer)

 Russ Shaw (Chief Financial Officer)

 Peel Hunt LLP - Nominated Adviser, Joint Broker                                                 +44 (0) 20 7148 8900
 James Steel / Oliver Duckworth

 finnCap Ltd - Joint Broker                          +44 (0) 20 7220 0500
 Geoff Nash / George Dollemore

 Walbrook PR - Financial PR & IR Adviser                       +44 (0) 20 7933 8780
 Paul McManus / Anna Dunphy            Or Genedrive@walbrookpr.com

 

 

About genedrive plc (http://www.genedriveplc.com)

 genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and robust point
of need molecular diagnostics platform for the diagnosis of infectious
diseases and for use in patient stratification (genotyping), pathogen
detection and other indications. The company are currently developing a
genetic test for CYP2C19 metaboliser status.

The Genedrive® MT-RNR1 ID Kit, selected as 1 of the 10 EVA pilot projects,
is the world's first commercial point-of-care genetic test for emergency care.
It helps to avoid irreversible lifelong hearing loss in specific infants
exposed to aminoglycosides by rapidly detecting the m.1555A>G gene variant
that can cause lifelong deafness, allowing for alternative antibiotics to be
prescribed. Product information can be found at
https://www.genedrive.com/assays/rnr1-product.php

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGSEEFSLEDSEIL